Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Reiterates Buy on Coursera, Maintains $19 Price Target

Needham Reiterates Buy on Coursera, Maintains $19 Price Target

Needham analyst Ryan MacDonald reiterates Coursera (NYSE:COUR) with a Buy and maintains $19 price target.

byBenzinga Newsdesk

February 10, 2023

1 minute read

Needham analyst Ryan MacDonald reiterates Coursera (NYSE:COUR) with a Buy and maintains $19 price target.

Elon Musk Offers His Suggestion For China And Taiwan: ‘Figure Out A Special Administrative Zone’

By Chris Katje

October 9, 4:35 PM

The world’s richest person has weighed in on the war between Ukraine and Russia recently.

AAPL

Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here

By Lara Goldstein

September 21, 12:00 AM

The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its developer, Enveric Biosciences (NASDAQ: ENVB).

ENVB

Analyst Ratings

Where Newmont Stands With Analysts

By Benzinga Insights

January 10, 12:00 PM

In the latest quarter, 4 analysts provided ratings for Newmont (NYSE:NEM), showcasing a mix of bullish and bearish…

NEM

Analyst Ratings

Analyst Ratings for Ambrx Biopharma

By Benzinga Insights

November 14, 2:01 PM

Ambrx Biopharma (NASDAQ:AMAM) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

AMAM

Needham Reiterates Buy on Coursera, Maintains $19 Price Target

Related Posts

Elon Musk Offers His Suggestion For China And Taiwan: ‘Figure Out A Special Administrative Zone’

Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here

Where Newmont Stands With Analysts

Analyst Ratings for Ambrx Biopharma